Oriva Therapeutics is a clinical-stage women’s health company focused on developing innovative therapies for the treatment of chronic gynaecological diseases with high unmet medical need. It includes two advanced programs: ORV-1362 for endometriosis and ORV-2499 for uterine fibroids, based on novel drug candidates. Headquartered in Barcelona, the company was founded in 2026 as a spin-off of projects originated by industry experts. Oriva is supported and invested in by Asabys Partners to advance the clinical development of the programs and improve women’s health.
Biotech
Ginecologia
Drug development
Marta Llorens Borrell
Head Clinical Operations
Agnès Arbat
Chief Executive Officer (CEO)
Rosa Torres
Ljudmila Katchan
